Le Lézard
Classified in: Health, Business
Subjects: AWD, NPT, TDS, PSF, FVT

National Safety Council to Award Up to $260,000 to Expand Grant Programs to Solve Most Common Workplace Injury


With inaugural grant cycle underway, MSD Solutions Lab initiative launches 2024 programs to continue advancing musculoskeletal disorder research and innovation   

WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- Following the debut of the Research to Solutions (R2S) grant and MSD Solutions Pilot Grant in 2023, the National Safety Council is awarding up to an additional $260,000 this year through these pioneering grant programs to help uncover promising new safety solutions to prevent work-related musculoskeletal disorders, or MSDs. As a key initiative of the Council's MSD Solutions Lab, a groundbreaking strategic program established in 2021 with funding from Amazon (NASDAQ: AMZN), a total of up to $535,000 has now been committed in grants to foster innovative, transferable methods to mitigate MSDs ? the most common workplace injury ? across a range of sectors and workplaces.  

"Bringing together the brightest minds and pushing the boundaries of MSD prevention research and technology is at the heart of all we do," said Paul Vincent, NSC executive vice president of workplace practice. "We're proud to bring back these grants for another year so we can expand our network of top innovators to solve this pervasive safety challenge, and ultimately help workers lead safer, healthier lives on and off the job."

"We are pleased to continue our partnership with NSC on the MSD Solutions Lab," said Sarah Rhoads, Vice President of Global Workplace Health and Safety at Amazon. "The Research to Solutions and MSD Pilot Grant programs will advance research and create scalable MSD mitigation programs that help improve safety for employees on a global scale."

MSDs include tendinitis, back strains and sprains, as well as carpal tunnel syndrome, and are often caused by exposures to repetitive, forceful exertions like heavy lifting. They affect people in every industry and sector, and cost U.S. businesses in the private sector nearly $17 billion a year, according to the Liberty Mutual Workplace Safety Index. Recognizing the scope of these injuries, each grant is designed to further MSD prevention:

NSC will announce the list of this year's grant recipients in May 2024 and the winners will have an opportunity to present their safety findings at the 2025 NSC Safety Congress & Expo or another event. For the current 2023-2024 grant cycle, the inaugural recipients will share their key learnings and research at this year's NSC Safety Congress & Expo in Orlando, Florida from September 16-18. Winners also shared progress reports with the MSD Solutions Lab before the end of 2023.

The R2S and MSDs Pilot Grant are two of several initiatives supported by the MSD Solutions Lab to achieve its goal of preventing MSDs. To learn more about these efforts, visit nsc.org/msd. To learn more about the grant programs and application requirements, click here.

About the National Safety Council
The National Safety Council is America's leading nonprofit safety advocate ? and has been for 110 years. As a mission-based organization, we work to eliminate the leading causes of preventable death and injury, focusing our efforts on the workplace and roadways. We create a culture of safety to not only keep people safer at work, but also beyond the workplace so they can live their fullest lives.

Connect with NSC:
Facebook
Twitter
LinkedIn
YouTube
Instagram

SOURCE National Safety Council


These press releases may also interest you

at 04:09
A news report from China Daily: The 2024 ZGC Forum in Beijing showcased a wide range of latest technological innovations. The event ran from April 25 to 29 and comprised 128 activities, including forums and conferences, technology exchanges,...

at 04:05
Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , disclosed today that under the...

at 03:38
Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January ? March...

at 03:05
The European Academy of Allergy and Clinical...

at 03:00
BioWorldtm published by  Clarivate Plc , a leading global provider of transformative intelligence, explores the growing investment in CAR T therapy development in mainland China in a new series titled "China's CAR T market comes of age." The report...

at 03:00
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab...



News published on and distributed by: